Acadia Healthcare (ACHC): Buy, Sell, or Hold Post Q2 Earnings? Anthony Lee Wed, October 7, 2026 at 11:20 AM EDT 3 min read ACHC +0.96% ^GSPC -0.34% Trade ACHC on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Acadia Healthcare trades at $28.83 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 17.5%.
Is there a buying opportunity in Acadia Healthcare, or does it present a risk to your portfolio? See what our analysts have to say in our full research report, it's free.
We're passing on Acadia Healthcare for now. Here are three reasons we avoid ACHC, plus one stock we'd rather own.
Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful Hospital Chains company because there's a ceiling to what customers will pay.
Acadia Healthcare's admissions came in at 54,141 in the latest quarter, and over the last two years, averaged 4.5% year-on-year growth. This performance slightly lagged the sector and suggests it might have to lower prices or invest in product improvements to accelerate growth, factors that can hinder near-term profitability.
We track the long-term change in earnings per share (EPS) because it highlights whether a company's growth is profitable.
Sadly for Acadia Healthcare, its EPS declined by 12.4% annually over the last five years while its revenue grew by 8.7%. This tells us the company became less profitable on a per-share basis as it expanded.
A company's ROIC, or return on invested capital, shows how much operating profit it makes compared to the money it has raised (debt and equity).
Unfortunately, Acadia Healthcare's ROIC has decreased significantly over the last few years. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.
Acadia Healthcare doesn't pass our quality test. That said, the stock currently trades at 17.1× forward P/E (or $28.83 per share). This valuation tells us a lot of optimism is priced in - we think there are better opportunities elsewhere. We'd suggest looking at the most entrenched endpoint security platform on the market.
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
